Calendario›ARWR›Plozasiran

Plozasiran

Treatment Protocol of Plozasiran in Adults With High-Risk Severe Hypertriglyceridemia (SHTG) and in Adults and Adolescents With FCS

Ensayo de ARROWHEAD PHARMACEUTICALS, INC. en Quilomicronemia familiar · Hipertrigliceridemia grave de alto riesgo (SHTG).

Fase

no aplica

Estado

Disponible por acceso ampliado

Centros

1

Qué significa cada fase y cada estado.

Estudio de acceso ampliado.

Cómo lo describe el promotor

En el documentoEn inglés, del registroThis is a treatment program for the use of plozasiran in adults (AROAPOC3-EAP-002) and adolescents (AROAPOC3-EAP-003) with familial chylomicronemia syndrome (FCS) as well as in adults (AROAPOC3-EAP-004) with high risk severe hypertriglyceridemia (SHTG). The program will enroll eligible patients ≥ 15 years of age, with fasting triglycerides (TGs) ≥ 880 mg/dL (≥ 10 mmol/L) that is not adequately controlled with standard lipid-lowering therapy, and with a diagnosis of FCS. Patients will receive 25 mg of plozasiran by subcutaneous (sc) injection on Day 1 and every 3 months for a total of 5 injections. The duration of the program is 15 months. The program will also enroll eligible patients ≥18 years of age, with fasting TGs \> 880 mg/dL (\> 9.94 mmol/L), or fasting TGs \> 500 mg/dL plus a history of acute pancreatitis, that are not adequately controlled with standard lipid-lowering therapy, and with a diagnosis of high risk SHTG. SHTG patients will receive 25 mg of plozasiran by sc injection on Day 1 and every 3 months for a total of 7 injections. The duration of the program is 21 months.

Más ensayos de ARWR

Todos los de ARWR, en su ficha.

Ficha completa en ClinicalTrials.gov (NCT06796426), actualizada en mar 2026.